ibritumomab tiuxetan   Click here for help

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®
Approved drug Immunopharmacology Ligand
ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))
Compound class: Antibody
Comment: A monoclonal antibody used as a radioimmunotherapy treatment.
No information available.
Summary of Clinical Use Click here for help
Used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (labelled with the high energy beta emitter, Yttrium-90). Can be labelled with Indium-111 for diagnostic investigation/imaging.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Yttrium-90 conjugated anti-CD20 monoclonal antibody. Once bound to CD-20 +ve B-cells of the lymphoma, the beta particles act locally to destroy the cancerous cells.
External links Click here for help